ReviewThe Lancet. Infectious diseases2017
Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.
Review in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Multidimensional determinants of BCG-induced false-positivity in tuberculin skin testing: a global meta-analysis of 242 studies.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Pooled it
- Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019.MMWR. Morbidity and mortality weekly report · 2019Guideline
- Randomized Controlled Trial of Clinical Guidelines Versus Interactive Decision-Support for Improving Medical Trainees' Confidence with Latent Tuberculosis Care.Journal of general internal medicine · 2024Trial
- Asynchronous Video Directly Observed Therapy to Monitor Short-Course Latent Tuberculosis Infection Treatment: Results of a Randomized Controlled Trial.Open forum infectious diseases · 2024Trial
- Characteristics of Plausible Source Cases Responsible for Recent Mycobacterium tuberculosis Transmission, United States, 2018-2022.Emerging infectious diseases · 2026Article
- Education and Training Needs of U.S. Tuberculosis Programs.Health promotion practice · 2026Article
- Article
- Risk Perceptions Regarding Tuberculosis Among Hispanic Adults - United States, 2020-2022.American journal of health promotion : AJHP · 2026Article
- A Blood and Biochemical Indicator-Based Prognostic Model Predicting Latent Tuberculosis Infection: A Retrospective Study.Tropical medicine and infectious disease · 2025Article
- Trends and delays in pulmonary tuberculosis diagnosis among elderly patients (≥ 60 Years) in Southern China: a 13-year surveillance data analysis (2010-2022).BMC public health · 2025Article
- Development and validation of prediction algorithm to identify tuberculosis in two large California health systems.Nature communications · 2025Article
- Identification and functional characterization of glycosyltransferase-related biomarkers for tuberculosis diagnosis.AMB Express · 2025Article
- Knowledge and Prevalence of Latent Tuberculosis Infection: A Feasibility and Pilot Study in a Primary Healthcare Setting in Rural Eastern Cape, South Africa.International journal of environmental research and public health · 2025Article
- Tuberculosis - United States, 2023.MMWR. Morbidity and mortality weekly report · 2024Article
- Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.American journal of clinical dermatology · 2024Observational
- Test and treat approach for tuberculosis infection amongst household contacts of drug-susceptible pulmonary tuberculosis, Mumbai, India.Frontiers in tuberculosis · 2024Article
- Article
- Scaling Up Latent Tuberculosis Infection Testing and Treatment for Non-US Born Patients in a Federally Qualified Community Health Center.Journal of immigrant and minority health · 2023Article
- Trends in tuberculosis clinicians' adoption of short-course regimens for latent tuberculosis infection.Journal of clinical tuberculosis and other mycobacterial diseases · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Since 1989, the USA has been pursuing the goal of tuberculosis elimination. After substantial progress during the past two decades, the rate of tuberculosis cases in the USA each year has now levelled off and remains well above the elimination threshold. Both epidemiological data and modelling underline the necessity of addressing latent tuberculosis infection if further progress is to be made in eliminating the disease. In this Personal View we explore next steps towards elimination. Given the estimated prevalence of latent tuberculosis infection, compared with the limited testing and treatment that currently occur, a major new effort is required. This effort should consist of a surveillance system or registry to monitor progress, scale-up of targeted testing for latent tuberculosis infection in at-risk populations, scale-up of short-course treatment regimens, engagement of affected communities and medical providers who serve those communities, and increased public health staffing for implementation and oversight. Such an effort would benefit greatly from the development of new tools, such as tests that better indicate reactivation risk, and even shorter latent tuberculosis infection treatment regimens than currently exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.